-
China Unveils Management Measures to Strengthen National Health Emergency Teams
•
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration have jointly issued the “Measures for the Management of National Health Emergency Teams,” a directive aimed at bolstering and standardizing the management of national health emergency teams to enhance emergency response capabilities…
-
China’s NHC Mandates Enhanced Management and Accessibility of Midwifery Services
•
The National Health Commission (NHC) has issued a notification with the aim of enhancing the management of midwifery services, outlining a total of six requirements to improve accessibility and service quality. The first requirement is to strengthen the planning and layout of midwifery services, with the goal of promoting provincial…
-
AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software
•
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic pulmonary fibrosis (IPF) candidate, tralokinumab, which has contributed to the development of Brainomix’s e-Lung software. This AI-enabled tool, announced by the UK medtech company this week, is designed to identify patients at risk of decline…
-
BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies
•
A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has revealed that the company has terminated its earlier partnership with US biotech firm Shoreline Therapeutics Inc. The agreement, which was set to be effective from the first quarter of 2024, did not provide a specific…
-
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its financial performance for 2023, along with recent business updates. The group reported a total revenue of RMB 6.143 billion (USD 850 million), marking a 2.7% year-on-year (YOY) growth. Their oncology, cardiovascular, central nervous system (CNS),…
-
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced its financial report for 2023. The company reported a 33.9% year-on-year (YOY) increase in revenue, reaching RMB 336 million (USD 46.5 million), with gross profits surging 41.8% to RMB 223 million (USD…
-
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report for 2023, highlighting a total revenue growth of 5.9% year-on-year (YOY) to RMB 222 million (USD 30.7 million). This figure includes product sales amounting to RMB 194 million (USD 26.8 million). The company’s marketing and…
-
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
•
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for 2023, recording revenues of RMB 345.2 million (USD 47.7 million), a decrease of 67% year-on-year (YOY). This decline is primarily attributed to the reduced demand for COVID-19 vaccines, resulting in a RMB 253.2 million refund.…
